SDIC Venture Capital

SDIC Venture Capital (国投创业基金) is a state-backed investment fund active in China's venture capital market, particularly in technology and healthcare sectors. In early 2025, it led an oversubscribed A+ round of over 100 million RMB for Kailan Pharma, a cholesterol metabolism drug developer, with existing shareholder AstraZeneca Golden Bay Healthcare Industry Fund also adding to its position . The fund appears frequently alongside other state capital vehicles in deals involving strategic industries—暗涌Waves noted its presence in a 700 million RMB club deal for domestic CAD software supplier New迪数字, alongside government-backed funds like Bohai Industrial Investment Fund and Shenzhen High-Tech Investment . In the new energy sector, SDIC Venture Capital was identified as one of the most active state-affiliated investors, grouped with SDIC Innovation, SDIC Chuangyi, and others under the broad category of "state-owned investment institutions" .